For almost 20 years, we have become the most professional manufacturer in the world, No.1 in China in the methylfolate industry. With strict quality guarantee system, strong brand awareness and high-level after sale service, our company is famous for the business philosophy “Only manufacture and supply premium quality products.”
Methylenetetrahydrofolate reductase (MTHFR) is one of the key enzymes in the metabolism of folate and homocysteine (Hcy), and is involved in the occurrence of neuropsychiatric diseases such as Alzheimer's disease and depression.
MTHFR genetic defects will affect the body's use of folic acid, causing pregnancy-induced hypertension, spontaneous abortion, fetal neural tube defects, congenital heart disease, cleft lip and palate, etc. Insufficient amount of effectively used folate can lead to birth defects and adverse pregnancy outcomes, but is also a high-risk factor for infant intellectual development, maternal depression, and child autism.
MTHFR genotype causes abnormality of folate metabolism and related disease mechanism
North American health authorities recommend 0.4 mg/day folic acid before conception and throughout pregnancy to reduce the risk of neural tube defects. As usual, there are folic acid and L-Methylfolate for pregnants.
Actually, in almost all tissues, including the brain, folates are required for one-carbon transfer reactions, which are essential for the synthesis of DNA and RNA nucleotides, the metabolism of amino acids and the occurrence of methylation reactions.
A crystalline salt form is a key requirement for a satisfactory stability in capsules or tablets, so Magnafolate® is less likely to lose its potency over time.
Copyright © 2021 Lianyungang Jinkang Hexin Pharmaceutical Co.,Ltd. All Rights Reserved jinkang-chem